HANSOH PHARMA (03692) announced that on August 26, 2025, its innovative drug Xinyue® (inebilizumab injection) received a drug registration certificate issued by China's National Medical Products Administration (NMPA), approving an additional indication for the treatment of adult patients with immunoglobulin G4-related disease (IgG4-RD). This marks the second approved indication for Xinyue®, which was previously included in NMPA's priority review and approval process on February 8, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.